Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-23-000221
Filing Date
2023-02-23
Accepted
2023-02-23 15:23:08
Documents
2
Group Members
ORBIMED ADVISORS IV LTDORBIMED ASIA GP IV, L.P.ORBIMED CAPITAL GP VII LLCORBIMED CAPITAL GP VIII LLCORBIMED CAPITAL LLCORBIMED GENESIS GP LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 ss1802046_sc13da.htm SC 13D/A 188361
2 JOINT FILING AGREEMENT ss1802046_ex9901.htm EX-99.1 10836
  Complete submission text file 0000947871-23-000221.txt   200908
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130
Business Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130 8582994699
Kinnate Biopharma Inc. (Subject) CIK: 0001797768 (see all company filings)

EIN.: 824566526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91893 | Film No.: 23659253
SIC: 2834 Pharmaceutical Preparations